Huntington National Bank’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $163K | Buy |
718
+117
| +19% | +$20.8K | ﹤0.01% | 979 |
|
|
2026
Q1 | $104K | Sell |
601
-23
| -4% | -$4.26K | ﹤0.01% | 1072 |
|
|
2025
Q4 | $124K | Buy |
624
+4
| +0.6% | +$726 | ﹤0.01% | 907 |
|
|
2025
Q3 | $97K | Sell |
620
-56
| -8% | -$8.89K | ﹤0.01% | 997 |
|
|
2025
Q2 | $103K | Buy |
676
+378
| +127% | +$50.4K | ﹤0.01% | 946 |
|
|
2025
Q1 | $44.9K | Sell |
298
-2
| -0.7% | -$335 | ﹤0.01% | 1225 |
|
|
2024
Q4 | $55.4K | Buy |
300
+164
| +121% | +$31.6K | ﹤0.01% | 1155 |
|
|
2024
Q3 | $26.8K | Sell |
136
-111
| -45% | -$23.1K | ﹤0.01% | 1415 |
|
|
2024
Q2 | $51K | Sell |
247
-3
| -1% | -$680 | ﹤0.01% | 1112 |
|
|
2024
Q1 | $67.7K | Buy |
250
+32
| +15% | +$7.64K | ﹤0.01% | 1010 |
|
|
2023
Q4 | $51.5K | Sell |
218
-50
| -19% | -$9.83K | ﹤0.01% | 1068 |
|
|
2023
Q3 | $52.5K | Sell |
268
-73
| -21% | -$15K | ﹤0.01% | 1025 |
|
|
2023
Q2 | $71.7K | Buy |
341
+122
| +56% | +$24.3K | ﹤0.01% | 929 |
|
|
2023
Q1 | $44.2K | Buy |
219
+17
| +8% | +$3.85K | ﹤0.01% | 1043 |
|
|
2022
Q4 | $44K | Buy |
202
+13
| +7% | +$2.84K | ﹤0.01% | 1046 |
|
|
2022
Q3 | $37K | Buy |
189
+66
| +54% | +$14.2K | ﹤0.01% | 1077 |
|
|
2022
Q2 | $26K | Buy |
123
+11
| +10% | +$2.69K | ﹤0.01% | 1222 |
|
|
2022
Q1 | $32K | Sell |
112
-11
| -9% | -$3.39K | ﹤0.01% | 1204 |
|
|
2021
Q4 | $46K | Sell |
123
-1
| -0.8% | -$389 | ﹤0.01% | 1095 |
|
|
2021
Q3 | $51K | Sell |
124
-53
| -30% | -$22K | ﹤0.01% | 964 |
|
|
2021
Q2 | $65K | Buy |
177
+55
| +45% | +$18.4K | ﹤0.01% | 868 |
|
|
2021
Q1 | $35K | Buy |
122
+67
| +122% | +$18.6K | ﹤0.01% | 941 |
|
|
2020
Q4 | $14K | Buy |
55
+54
| +5,400% | +$12.9K | ﹤0.01% | 1216 |
|
|
2020
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 1546 |
|
|
2020
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 1531 |
|
|
2020
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 1580 |
|
|
2019
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 1683 |
|
|
2019
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 1555 |
|
|
2019
Q2 | $0 | Buy |
+1
| New | +$136 | ﹤0.01% | 1603 |
|
|
2019
Q1 | – | Sell |
-1
| Closed | – | – | 1586 |
|
|
2018
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 1678 |
|
|
2018
Q3 | $0 | Buy |
+1
| New | +$123 | ﹤0.01% | 1697 |
|
Other funds holding CRL
AI
Huntington National Bank's CRL Position: Q2 2026 in Review
Huntington National Bank increased its Charles River Laboratories (CRL) stake by 19% in Q2 2026, buying an estimated $20.8K and bringing the position to 718 shares worth $163K. The position accounts for ﹤0.01% of the portfolio, ranked #979.
Huntington National Bank first reported a position in CRL in Q3 2018 and has held it in 31 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Huntington National Bank held 718 shares of Charles River Laboratories worth $163K as of Q2 2026.
- Huntington National Bank bought 117 Charles River Laboratories shares in Q2 2026, an estimated $20.8K.
- Charles River Laboratories made up ﹤0.01% of Huntington National Bank's portfolio in Q2 2026, its #979 holding.
- Huntington National Bank first reported a position in Charles River Laboratories in Q3 2018 and has held it in 31 quarters since.
- 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Huntington National Bank's 13F filing for Q2 2026, filed 13 Aug 2026.